-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, Shanghai Cell Therapy Group announced that it has successfully completed the D1 round of nearly 500 million yuan in financing.
fund
Shanghai Cell Therapy Group was established in 2013 and is dedicated to the cell therapy of tumors.
In terms of product pipeline, its non-viral vector CD19 CAR-T cell injection (BZ019) is currently the first CAR-T cell therapy drug prepared by a non-viral vector that has been approved to enter the clinic.
CAR-T
At present, the cell production center under construction of the company is expected to be completed by the end of April this year.
In addition, it is worth mentioning that in 2020, Shanghai Mengchao Tumor Hospital, established by Shanghai Cell Therapy Group with an investment of 800 million yuan, will officially operate and become an affiliated hospital of Shanghai University, becoming a clinical research hospital featuring " immunotherapy +".
Immunity leave a message here